IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Janak PADIA et al

Title:

UREA DERIVATIVES AS INHIBITORS FOR CCR-3

RECEPTOR

Appl. No.:

Unassigned

Filing Date: 01/02/02

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR §1.56</u>

Commissioner for Patents **Box PCT** Washington, D.C. 20231


Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.



RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO-1449 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language documents has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609). An English language abstract is attached for Document A5.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Stephen A. Bent

Attorney for Applicants Registration No. 29,768

Date January 2, 2002

FOLEY & LARDNER

Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

Telephone: Facsimile:

(202) 672-5407

(202) 672-5399

531 Rec'd P

02 JAN 2002

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 051023-0111 **APPLICANT** INFORMATION DISCLOSURE CITATION Janak PADIA et al FILING DATE **GROUP ART UNIT** (Use several sheets if necessary) January 2, 2002 Unassigned **U.S. PATENT DOCUMENTS DOCUMENT** FILING DATE **EXAMINER** SUB-REF DATE NAME CLASS INITIAL IF NUMBER **CLASS** APPROPRIATE Α1 4,880,802 11/14/1989 Schohe et al. 514 222.2 **FOREIGN PATENT DOCUMENTS** DOCUMENT TRANSLATION SUB-REF DATE COUNTRY **CLASS** NUMBER CLASS YES NO 0432442 06/19/1991 **EPO** A2 0903349 03/24/1999 **EPO** A3 Germany 888699 09/03/1953 Α4 Х 9-278737 10/28/1997 Japan A5 abstract OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) NAKAO, Kazuya et al. "Quantitative Structure - Activity Analyses of Novel Hydroxyphenylurea Derivatives as A6 Antioxidants," Bioorganic & Medicinal Chemistry (1998), Vol. 6, pp. 849-868. O'BRIEN, Patrick M. et al. "Inhibitors of Acyl-CoA:Cholestrerol O-Acyl Transferease (ACAT) as Hypocholesterolemic Agents. 8.1 Incorporation of Amide or Amine Functionalities into a Series of **A7** Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in Vitro and Efficacy in Vivo²", J. med. Chem. (1994), Vol. 37, No. 12, pp. 1810-1822, American Chemical Society. ROST, William J. et al. "N-Aralkyl-N-methylaminoethyl Carbanilates as Hypocholesteremic Agents," Journal **A8** of Pharmaceutical Sciences (1967), Vol. 56, No. 12, pp. 1598-1603. **EXAMINER DATE CONSIDERED** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this f rm with next communication to applicant.